Drugs / Tegoprazan
Tegoprazan
Trials 58 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 124 trials | ||||||
| Phase 1 | NCT07277712 | Dec 2025 → May 2026 overdue | — | HK inno.N Corporation | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06332638 | Mar → Jul 2024 | — | HK inno.N Corporation | Unknown | No outcome recorded |
| Phase 1 | NCT06164834 | Dec 2023 → Nov 2024 | — | HK inno.N Corporation | Unknown | No outcome recorded |
| Phase 1 | NCT05915871 | Mar → Apr 2023 | — | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05723510 | Mar → Jul 2023 | — | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 1 | NCT05883306 | Jun → Jul 2022 | — | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05353010 | May → Jul 2022 | — | HK inno.N Corporation | Unknown | No outcome recorded |
| Phase 1 | NCT04568772 | Nov 2020 → Jul 2021 | gastroesophageal reflux disease | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT04587011 | Sep 2020 → Mar 2021 | — | HK inno.N Corporation | Unknown | No outcome recorded |
| Phase 1 | NCT04494269 | Sep 2020 → Jun 2023 | — | HK inno.N Corporation | Unknown | No outcome recorded |
| Phase 1 | NCT04231136 | Jan → Jul 2020 | — | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 1 | NCT04221321 | Jan → Mar 2020 | — | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 1 | NCT04171687 | Oct 2019 → Feb 2020 | — | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03863938 | Mar → Apr 2019 | — | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03814642 | Jan → Jul 2019 | — | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03530228 | May → Aug 2018 | — | HK inno.N Corporation | Unknown | No outcome recorded |
| Phase 1 | NCT03458650 | Mar → Apr 2018 | — | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03378284 | Dec 2017 | — | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03011996 | May 2016 → Feb 2017 | — | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03043521 | May → Aug 2015 | — | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03009760 | Jan 2015 → Apr 2016 | — | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02052336 | Oct 2013 → Jan 2014 | — | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01830309 | Jan → Feb 2013 | — | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01473173 | Nov 2011 → Aug 2012 | — | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07708545 | Jul → Dec 2026 expected | peptic ulcer disease | Indonesia University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05933031 | Feb 2023 → Dec 2024 | Helicobacter pylori infectious disease | HK inno.N Corporation | Unknown | No outcome recorded |
| Phase 2 | NCT02028663 | May 2013 → May 2014 | esophagitis, gastroesophageal reflux disease | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07242456 | Feb → Nov 2025 overdue | Helicobacter pylori infectious disease | First People's Hospital of Hangzhou | Recruiting | No outcome recorded |
| Phase 314 trials | ||||||
| Phase 3 | NCT07687706 | Jan 2026 → Jun 2027 expected | transient ischemic attack | Hanyang University Guri Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT05577468 | Oct 2022 → Sep 2023 | Helicobacter pylori infectious disease | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT05010954 | Oct 2021 → Sep 2022 | duodenal ulcer | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04840550 | May 2021 → Jun 2024 | peptic ulcer disease | HK inno.N Corporation | Unknown | No outcome recorded |
| Phase 3 | NCT04128917 | Jan → Dec 2020 | Helicobacter pylori infectious disease | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 3 | NCT04022096 | Jun 2019 → Jun 2021 | esophagitis | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 3 | NCT03591653 | Oct 2018 → Oct 2019 | gastroesophageal reflux disease | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03615677 | Oct 2018 → Oct 2019 | esophagitis | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03498456 | Jun 2018 → Dec 2019 | Helicobacter pylori infectious disease | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 3 | NCT03317223 | Oct 2017 → Jan 2019 | Helicobacter pylori infectious disease | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 3 | NCT03006874 | May 2016 → Mar 2017 | esophagitis | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 3 | NCT02761512 | May 2016 → Jul 2018 | gastric ulcer | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 3 | NCT02556021 | Sep 2015 → Nov 2016 | gastroesophageal reflux disease | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 3 | NCT02456935 | May 2015 → Jul 2016 | esophagitis | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 411 trials | ||||||
| Phase 4 | NCT06743243 | Jul 2025 → Oct 2026 expected | — | Seok Kyeong Oh | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT06523764 | Nov 2024 → Aug 2025 overdue | chronic gastritis | Xijing Hospital of Digestive Diseases | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06991348 | Jul 2024 → Nov 2025 overdue | gastroesophageal reflux disease | Carnot Laboratories | Recruiting | No outcome recorded |
| Phase 4 | NCT05647278 | Nov 2023 → Sep 2025 | Helicobacter pylori infectious disease | Zhang Xiaofeng,MD | Completed | No outcome recorded |
| Phase 4 | NCT05701540 | Mar 2023 → Dec 2024 | gastroesophageal reflux disease | HK inno.N Corporation | Unknown | No outcome recorded |
| Phase 4 | NCT05438550 | Feb → Dec 2023 | Helicobacter pylori infectious disease | Shandong University | Unknown | No outcome recorded |
| Phase 4 | NCT05586113 | Feb → Oct 2023 | Helicobacter pylori infectious disease | Shandong University | Unknown | No outcome recorded |
| Phase 4 | NCT04416581 | May 2021 → Dec 2027 expected | acute coronary syndrome, coronary artery disorder, myocardial infarction | Duk-Woo Park, MD | Recruiting | No outcome recorded |
| Phase 4 | NCT05267743 | Feb 2021 → May 2022 | gastroesophageal reflux disease | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 4 | NCT04449185 | Jun 2020 → Oct 2021 | dyspepsia | Asan Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT04309916 | May 2020 → Nov 2021 | gastroesophageal reflux disease | HK inno.N Corporation | Completed | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT06977841 | Jun 2025 → Mar 2026 | — | Zhongshan Hospital (Xiamen), Fudan University | Completed | No outcome recorded |
| — | NCT06894992 | May → Dec 2025 overdue | active peptic ulcer disease | Mario Steffanus | Recruiting | No outcome recorded |
| — | NCT05870683 | May → Oct 2023 | Helicobacter pylori infectious disease | Yanqing Li | Unknown | No outcome recorded |
| — | NCT04674774 | Mar 2021 → Feb 2022 | Helicobacter pylori infectious disease | Incheon St.Mary's Hospital | Unknown | No outcome recorded |
| — | NCT06382493 | Feb 2021 → Dec 2026 expected | Helicobacter pylori infectious disease | Seoul National University Bundang Hospital | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 12 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06561542 Comparator | Aug 2024 → Nov 2025 overdue | — | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT04639804 Comparator | Jun → Jul 2020 | — | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 1 | NCT04066257 Comparator | Jan → Feb 2019 | — | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02995239 Comparator | Apr 2015 | esophagitis | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05871398 Comparator | Oct 2019 → Dec 2021 | gastroesophageal reflux disease | Pusan National University Hospital | Completed | No outcome recorded |
| Phase 46 trials | ||||||
| Phase 4 | NCT07405697 Comparator | Feb 2026 → Dec 2027 expected | Helicobacter pylori infectious disease | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07405684 Comparator | Feb 2026 → Dec 2027 expected | Helicobacter pylori infectious disease | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07242443 Background | Nov 2025 → Oct 2026 expected | Helicobacter pylori infectious disease | First People's Hospital of Hangzhou | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06318104 Comparator | Apr → Nov 2024 | Helicobacter pylori infectious disease | Hospital General de México Dr. Eduardo Liceaga | Unknown | No outcome recorded |
| Phase 4 | NCT06351891 Background | Apr → Dec 2024 | Helicobacter pylori infectious disease | Qilu Hospital of Shandong University | Unknown | No outcome recorded |
| Phase 4 | NCT05786807 Background | Mar 2022 → Nov 2023 | functional gastric disease | Wonkwang University Hospital | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06340334 Background | Mar 2024 → Sep 2025 | Helicobacter pylori infectious disease | Nanjing First Hospital, Nanjing Medical University | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 73 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tegoprazan | “Based on the susceptibility results and penicillin-allergic test, a tailored 7-day triple or quadruple therapy regimen is prescribed, including Tegoprazan , Amoxicillin,...” NCT07405697 ↗54“This study evaluates the effect of food consumption on the pharmacokinetic and pharmacodynamic properties of tegoprazan after a single oral dose in healthy men.” PMID 34246485 ↗ Jul 2021 “including Tegoprazan , Amoxicillin, Clarithromycin, Levofloxacin, Bismuth Potassium Citrate, Metronidazole, Doxycycline or Minocycline.” NCT07405684 ↗ “Tegoprazan (LXI-15028), a novel potassium-competitive acid blocker, has shown great efficacy in treating acid-related disorders.” PMID 40349123 ↗ May 2025 “Efficacy and safety of tegoprazan (LXI-15028) vs . esomeprazole in patients with erosive esophagitis” PMID 39474720 ↗ Oct 2024 “Tegoprazan (50mg twice/day before breakfast and supper)” NCT06351891 ↗ “Tegoprazan 50 mg 1 tab twice daily” NCT05786807 ↗ “P-CAB (tegoprazan 50mg once daily)” PMID 40188976 ↗ Apr 2025 |
| Known as | CJ-12420 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02761512 ↗ |
| Known as | IN-A001 | “IN-A001 50mg(Tegoprazan 50mg” NCT05353010 ↗ |
| Known as | K-CAB | “A Randomized, Open-label, Single-dose Phase 1 Clinical Trial to Compare the Effect of Timing of Food on the Pharmacokinetics and Pharmacodynamics of K-CAB (Tegoprazan) in...” NCT03863938 ↗ |
| Known as | LXI-15028 | “Tegoprazan (LXI-15028), a novel potassium-competitive acid blocker, has shown great efficacy in treating acid-related disorders.” PMID 40349123 ↗ May 2025 |
| Action | Inhibit | “potassium-competitive acid blocker that suppresses gastric acid secretion” PMID 34227708 ↗ Jul 2021 |
| Modality | Other / unclassified | “Tegoprazan is a potassium-competitive acid blocker used for gastric acid suppression” PMID 35787943 ↗ Jul 2022 |
| Route | Oral | “multiple-dose pharmacodynamics (PD) of orally administered CJ-12420 and esomeprazole in healthy male subjects.” NCT01473173 ↗ |